Monday, June 5, 2023
This activity is intended for pharmacists who manage and/or treat patients with type 2 diabetes.
The goal of this activity is to examine the role of glucagon-like peptide-1 (GLP-1) agonists in meeting the needs of patients with type 2 diabetes. In addition, key points pharmacists should know about use of these agents and the role of the pharmacist in diabetes management will also be discussed in this clinical review.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Medscape, LLC designates this continuing education activity for 1.00 contact hour(s) (0.10 CEUs) (Universal Activity Number 0461-0000-11-028-H01-P ).
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
CE Released: 4/14/2011
Valid for credit through: 4/14/2012
processing....
Diabetes is a progressive, long-term, complex metabolic disorder that has a growing prevalence and economic burden. In 2010, it was estimated that there were 25.8 million people with either diagnosed or undiagnosed diabetes in the United States.[1] Notably, more than one fourth of cases of diabetes (7.0 million) are undiagnosed.[1] Diabetes is associated with an estimated $174 billion in direct and indirect costs, with approximately two thirds of that amount ($116 billion) due to direct medical expenditures.[1]
Diabetes has become a national epidemic. Figure 1 illustrates the trend in diagnosed diabetes in the United States from 1958 through 2008 with the prevalence increasing from 0.93% in 1958 to 6.29% in 2008.[2]
Figure 1. Trends in the prevalence of diagnosed diabetes in the United States. Data from the Centers for Disease Control and Prevention.[2]
The increased prevalence of diabetes mirrors the increased prevalence of overweight and obese individuals in the United States and underscores the important role of weight in the development of diabetes. Obesity, particularly visceral obesity, in conjunction with hypertension, is an important component of metabolic syndrome, a group of interrelated factors that increase the risk for cardiovascular disease.[3,4] In 2005-2006, the rates of overweight (body mass index [BMI] = 25-30 kg/m2), obesity (BMI ≥ 30 kg/m2), and extreme obesity (BMI ≥ 40 kg/m2) were 32.7%, 34.3%, and 5.9%, respectively.[5] Diabetes is also associated with a number of complications including the development of cardiovascular disease, kidney disease, and retinopathy.[1] Therefore, all healthcare professionals have an opportunity to educate patients regarding the appropriate management of diabetes.
